コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 creasing size with increased risk for covert malignancy.
2 tional control affects tumour initiation and malignancy.
3 apeutic potential of SK1 in this gynecologic malignancy.
4 of air leakage after pulmonary lobectomy for malignancy.
5 a more aggressive, metastasizing, and fatal malignancy.
6 ity in glioma specimens and grades of glioma malignancy.
7 was a true-positive result for HER2-positive malignancy.
8 with and 102 961 without pretransplant skin malignancy.
9 uminal epithelial cells in foci of prostatic malignancy.
10 oteins are frequently overexpressed in human malignancy.
11 confirming the role of BCR signaling in this malignancy.
12 ces may help distinguish Kimura disease from malignancy.
13 coordinately to promote GBM invasiveness and malignancy.
14 ar events in the advance of breast cancer to malignancy.
15 sed form is extremely uncommon and can mimic malignancy.
16 ted with cell proliferation, tumor grade and malignancy.
17 ortant dermoscopic features for detection of malignancy.
18 l-cell interactions as the characteristic of malignancy.
19 six dissected lymph nodes were negative for malignancy.
20 s and their signaling network contributes to malignancy.
21 ancer (EOC) is the most fatal gynaecological malignancy.
22 nority of infected persons ever develop this malignancy.
23 rs) and 721 developed hepatopancreatobiliary malignancy.
24 kt pathway is a well-known promoter of tumor malignancy.
25 ht be considered low-risk for progression to malignancy.
26 ted in adult animals but did not progress to malignancy.
27 ng the transition from normal homeostasis to malignancy.
28 genic hypomethylation signatures of advanced malignancy.
29 instability and resulting transformation to malignancy.
30 ctively stratified the risk of neoplasia and malignancy.
31 ted with increased risk of de novo (nonskin) malignancy.
32 nervous system is emerging as a regulator of malignancy.
33 eractivation of Wnt-signaling to prevent CRC malignancy.
34 tion plays a role in the development of this malignancy.
35 ective responses in patients with epithelial malignancies.
36 pair-related genes are prevalent across many malignancies.
37 ipients are at increased risk for developing malignancies.
38 als without clear diagnosis of hematological malignancies.
39 ted HIV-infected patients with hematological malignancies.
40 n effective therapeutic approach in multiple malignancies.
41 a desmosomal cadherin often overexpressed in malignancies.
42 rom the most indolent to the most aggressive malignancies.
43 nflammatory gene signature for human myeloid malignancies.
44 en shown to drive carcinogenesis in multiple malignancies.
45 nts affected by diverse forms of hematologic malignancies.
46 in the pathogenesis of this and other B cell malignancies.
47 enes may be targeted for treatment of HPV(+) malignancies.
48 nce ratio of $785, much lower than for other malignancies.
49 ed with cancer-specific outcomes in multiple malignancies.
50 is used with curative intent for hematologic malignancies.
51 rapy target in hematological and solid tumor malignancies.
52 ve been made in various areas of hematologic malignancies.
53 to an increased risk for several associated malignancies.
54 ntly deleted/mutated in human haematological malignancies.
55 icantly over time, especially in hematologic malignancies.
56 cs during hematopoiesis and in hematological malignancies.
57 atelet volume (MPV) is implicated in several malignancies.
58 operative optical imaging of GRPr-expressing malignancies.
59 ment option for several severe hematological malignancies.
60 attractive new approach to treat hematologic malignancies.
61 ing, in the treatment of MM and other B cell malignancies.
62 e successful treatment of all forms of human malignancies.
63 en performed in the setting of hematological malignancies.
64 e the development of gliomas and other human malignancies.
65 or the initiation and progression of various malignancies.
66 tients with Philadelphia-chromosome-positive malignancies.
67 d efficacy for the management of solid tumor malignancies.
68 rldwide and are associated with a variety of malignancies.
69 peutic strategy against MCL and other B-cell malignancies.
70 increased risk of developing haematological malignancies.
71 s are a genomic hallmark of many hematologic malignancies.
72 ombination therapy in GBM and possibly other malignancies.
73 for tumor-targeted radiotherapy of pediatric malignancies.
74 eloping AML and CML but no other hematologic malignancies.
75 agement of patients with GBM and other brain malignancies.
76 uently and simultaneously detected in B cell malignancies.
77 sive DNA damage should die and not grow into malignancies.
78 exemplified here as photodynamic therapy of malignancies.
79 n patients with mutant-IDH2 advanced myeloid malignancies.
80 sor protein that is altered in several human malignancies.
81 treatment for refractory or relapsed B-cell malignancies.
82 er haploidentical HSCT for high-risk myeloid malignancies.
83 tic strategies for treating CBL(mut) myeloid malignancies.
84 target for the treatment of non-hematologic malignancies.
85 hronic gastritis, peptic disease and gastric malignancies.
86 and overcome aberrant pathways in aggressive malignancies.
87 ed 18-55 years, had high-risk haematological malignancies.
88 ributed into solid tumors (122), hematologic malignancies (106), and nonmalignant immunosuppression (
89 ata and mutations identified in other B-cell malignancies, 1716 genes were sequenced in 113 FL tumor
91 age 50 years was highest in survivors of CNS malignancies (24.2 [95% CI 20.9-27.5]) and lowest in sur
92 in the context of chronic and acute myeloid malignancies; (3) age-related niche changes and their su
93 number of patients were found to have tongue malignancy (82%) followed by buccal mucosa and gingivobu
94 specific mortality and of developing de novo malignancies after transplantation compared with those w
95 g cholangitis (PSC) may be at higher risk of malignancy after liver transplantation (LT) compared to
99 sent in more than 30% of patients with solid malignancies and correlates with worsened patient surviv
100 es of spontaneous tumors, mainly hematologic malignancies and hepatocellular adenomas and carcinomas.
102 is commonly increased in leukemia and other malignancies and is associated with poor prognosis in le
103 of Cancer Registries, collected data on all malignancies and non-malignant neoplasms of the CNS diag
104 ce promotes the growth of endogenous colonic malignancies and of human colorectal cancer cell xenogra
106 ng that loss of NHEJ may be selected in some malignancies and that the deletion can be used as a mole
107 years or older who had solid or hematologic malignancies and underwent a geriatric assessment in one
108 patients with BD-IPMNs to determine risk of malignancy and define a subset of low-risk BD-IPMNs.
109 ibrils potentiate PI3K activation to promote malignancy and offer a perspective regarding the consist
110 tire cohort, including patients with myeloid malignancy and those receiving mismatched related/haploi
112 progression, is activated in numerous human malignancies, and is linked to chromosome instability.
113 ation in multiple phase I studies on various malignancies, and its clincal name is Pevonedistat.
114 ndergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary fu
115 massive osteochondral surgery for trauma or malignancy, and is confounded by potential concomitant b
116 xpression of protumoral genes, thrives tumor malignancy, and leads to the emergence of drug resistanc
117 elanoma is a complex and genomically diverse malignancy, and new genes and signaling pathways involve
118 ike cell-of-origin enhanced tumor incidence, malignancy, and the ability of mouse glioma cells (GC) t
119 e-leukemic cell interaction in human myeloid malignancies; and finally, (5) how the knowledge gained
120 RNA and protein are highly expressed in many malignancies as part of a signature of chromosome instab
122 this system was pervasive in diverse T cell malignancies assessed by pSTAT3/pSTAT5 phosphorylation.
123 imary effusion lymphoma (PEL), an aggressive malignancy associated with infection that is resistant t
124 of childhood cancer, the risk of subsequent malignancies at 15 years after initial cancer diagnosis
125 as much in common with other chronic myeloid malignancies at the genetic level, such as the clinicall
126 with BD-IPMNs without worrisome features of malignancy at 5 years was 18.8 (95% confidence interval,
127 ndividuals who were diagnosed with a primary malignancy at age 70 years or older and were treated wit
128 2 diabetes are significant risk factors for malignancies, being associated with chronic inflammation
129 and are used in the treatment of hematologic malignancies, block BCR-mediated lytic induction at clin
130 nt hypoxia (IH) mimicking OSA promotes tumor malignancy both directly and via host immune alterations
131 rearrangements are a common feature of human malignancies, but whether they represent bona fide cance
133 Mutations in cohesin contribute to myeloid malignancies by conferring enhanced self-renewal of hema
134 ss of DLG5 expression promoted breast cancer malignancy by inactivating the Hippo signaling pathway a
135 ical and clinical behaviors of hematological malignancies can be influenced by the active crosstalk w
137 ater precancerous lesions and in established malignancy can also occur in PIPs within normal human sk
138 uctal Adenocarcinoma (PDAC) is an aggressive malignancy characterised by the presence of extensive de
139 myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, extramedullary
140 al sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusio
147 g technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remo
148 ival and incidence of posttransplant de novo malignancies exist between recipients with PTM and those
151 ce of currently targeted antigens on several malignancies hamper the widespread application of immuno
152 approach to classification of hematological malignancies has evolved from descriptive approaches, ba
153 s in patients with mIDH advanced hematologic malignancies have demonstrated compelling clinical proof
154 umor-initiating cells for leukemia and other malignancies have long been the subject of intense and r
155 Malignant mesothelioma (MM) is an aggressive malignancy, highly resistant to current medical and surg
156 e is an extensively used model of MYC driven malignancy; however to date there has only been partial
157 001 and HR, 0.90; P = .03, respectively) and malignancy (HR, 0.68; P = .008 and HR, 0.77; P = .004, r
158 e fact that defects in signaling can lead to malignancy illustrates the need to control Notch activit
159 ctions of BACH2 and its regulation of B-cell malignancies in chronic hypoxic microenvironment have no
160 al management of, and screening for urologic malignancies in kidney transplant patients is warranted,
164 igen receptors, the incidence and pattern of malignancies in patients with PIDs do not reflect an inc
165 )) developed one and often several BAP1(-/-) malignancies in their lifetime, mostly malignant mesothe
167 in transfused patients and syndrome-specific malignancies in untransplanted patients, which may occur
168 nature predicted differences in survival for malignancies in which TILs were not known to have a prog
169 hepatocellular carcinoma (HCC) from non-HCC malignancy in a population of patients at risk for HCC.
170 us identifying ILT3 as a selective marker of malignancy in CLL and the first example of phenotypic co
173 ociated with a lower risk for posttransplant malignancy in kidney allograft recipients with negative
174 etic resonance (MR) imaging for diagnosis of malignancy in lesions that manifest as microcalcificatio
175 and specificity for detection of underlying malignancy in patients suspected of having a paraneoplas
176 (18)F-FDG PET/CT for detection of underlying malignancy in patients with clinically suspected neurolo
177 hese data show that ROCK2 activation induces malignancy in ras(Ha)-initiated/promoted papillomas in t
179 drenocortical carcinoma (ACC), a rare lethal malignancy in which aberrant Wnt/beta-catenin signaling
180 itically important therapy for hematological malignancies, inborn errors of metabolism, and immunodef
181 antileukemic effects on several hematologic malignancies including chronic myeloid leukemia (CML) an
182 is an emerging immunotherapy against several malignancies including glioblastoma, the most common and
185 utations have been discovered in many T-cell malignancies, including anaplastic lymphoma kinase (ALK)
186 ses (HPVs) are closely linked to major human malignancies, including cervical and head and neck cance
187 igate precursor to several lymphoplasmacytic malignancies, including immunoglobulin light-chain amylo
188 play a pathological role in diverse forms of malignancies, including multiple myeloma (MM), and thus
191 ches to molecular diagnostics in hematologic malignancies: indication-specific single gene assays, ge
192 the management of rheumatologic conditions, malignancies, inflammatory bowel disease, dermatologic c
196 coma (KS) as the most common AIDS-associated malignancy is etiologically caused by KS-associated herp
201 markable antitumor activity in hematological malignancies, it has been less effective in solid tumors
202 denocarcinoma (PDAC) is one of the deadliest malignancies lacking effective therapeutic strategies.
203 atological adverse events and second primary malignancies, lenalidomide maintenance therapy after ASC
204 more intensive screening for the presence of malignancies may be warranted in those with THSD7A-assoc
206 nt of Omega3FA effects on I/R, LR, and liver malignancy (n = 5/group), the latter through a syngeneic
208 st disease (GVHD) may increase risk of later malignancies of the head and neck and anogenital area.
211 ing the desmoplastic reaction and aggressive malignancy of mass-forming intrahepatic cholangiocarcino
212 le myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new approaches to treatme
213 allbladder cancer represents the most common malignancy of the biliary tract and is highly lethal wit
214 Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is the second leading cause of
218 : 3.23; 95% CI: 1.67-6.25) and hematological malignancies (OR: 2.85; 95% CI: 1.10-7.41) were associat
219 PO (a microenvironment factor in hematologic malignancies) or c-MPL-targeted pharmacological agents.
222 cinoma (PDA) is one of the most lethal human malignancies, owing in part to its propensity for metast
223 used primarily in germ cell, breast and lung malignancies, oxaliplatin is instead used almost exclusi
228 the OA/US device, assigned a probability of malignancy (POM) and BI-RADS category, and locked result
229 tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tum
231 here was no measurable association with age, malignancy, procedure, surgery length, operative blood l
232 plant recipients (SOTR) with a pretransplant malignancy (PTM) are at increased risk for cancer recurr
234 eventeen patients with histologically proven malignancy referred for clinical pBS were prospectively
235 ian cancer, the deadliest of the gynecologic malignancies, reflects major limitations associated with
241 and primary samples of human haematological malignancies, reveal that senescence-associated stemness
242 the risk and outcomes of second hematologic malignancies (SHMs) in a population-based cohort of pati
243 approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase
246 is a ubiquitous gamma herpesvirus linked to malignancies such as nasopharyngeal carcinoma, Burkitt's
247 k of subsequently developing a hematopoietic malignancy, suggesting that these mutations contribute t
248 very of rare STAT mutations in hematopoietic malignancies suggests that STAT mutants may be oncogenic
249 ion that patients with inherited hematologic malignancy syndromes may present without classic clinica
250 he rim pattern was more common among non-HCC malignancies than among HCCs for both readers (R1: 24 of
252 Anaplastic thyroid cancer (ATC) is a rare malignancy that accounts for 1%-2% of all thyroid cancer
253 hat pediatric non-DS-AMKL is a heterogeneous malignancy that can be divided into seven subgroups with
255 lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncoge
257 T-ALL) is a highly proliferative hematologic malignancy that results from the transformation of immat
258 good correlation to the measure of prostatic malignancy, the Gleason score, derived from individual p
259 tion of metabolic alterations in this lethal malignancy, the metabolic dependencies of obesity-associ
260 the imaging modality showed a suggestion of malignancy, there was a significant delay to final diagn
262 three overarching (1) unlike most epithelial malignancies, these sarcomas (excepting synovial sarcoma
263 ong-range interaction, which promotes cancer malignancy through enhancing expression of the genes rel
264 he treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with T
265 ter, phase 1 study in advanced hematological malignancies to assess the safety, efficacy, and recomme
267 ibility included adults with a hematological malignancy to receive myeloablative HCT from an availabl
268 d organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions
269 that tumor-associated T cells might promote malignancy via distinct mechanisms used by T cells in no
271 on of the COX-2 in IH-induced enhanced tumor malignancy was assessed using celecoxib as a COX-2 speci
273 ) of 764 patients, and a synchronous primary malignancy was confirmed in 5 patients (0.7%; 2 lung, 1
275 nmalignant immunosuppression and hematologic malignancies were independently associated with increase
276 eled prostate-specific membrane antigen-avid malignancies were rare (0.7%) in PC patients; atypical l
277 F-FDG PET/CT for the detection of underlying malignancy were 0.81 (95% CI, 0.76-0.86), 0.88 (95% CI,
280 = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demographic char
281 Is non-granular lesions have a high risk for malignancy, whereas proximally located 0-Is or 0-IIa gra
282 of patients with carcinosarcomas and related malignancies, which are often included under the broader
283 ) being investigated for treatment of B-cell malignancies, which has improved potency compared with o
284 pression level discriminated grades of tumor malignancies, which was consistent with its endogenous l
285 geted immunotherapy could eradicate a T cell malignancy while preserving sufficient normal T cells to
286 irth has repeatedly been linked to childhood malignancies, while few studies have focused on the offs
287 ods A total of 681 patients with hematologic malignancy who underwent transplantation in the United S
288 ents and 6,652 patients with a hematological malignancy who were admitted between 2009 and 2013 were
289 on women who had breast cancer and no prior malignancy, who were asymptomatic for metastatic lesions
290 Renal carcinoma is a common and aggressive malignancy whose histopathogenesis is incompletely under
292 herapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an at
293 ic target for the treatment of hematological malignancies with DDR defects, where ATM/p53-dependent a
295 mor and 13,538 patients with a hematological malignancy with an unplanned ICU admission between 1997
296 ho underwent surgery for exocrine pancreatic malignancy with curative intent were identified from a p
298 D7A-associated MN, eight of whom developed a malignancy within a median time of 3 months from diagnos
299 inder were excised, then 97.4% (37 of 38) of malignancies would have been diagnosed at surgery, and 3
300 ical stress is pervasive in egress routes of malignancy, yet the intrinsic effects of force on tumour
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。